Search
Now showing items 11-15 of 15
Cpt1c downregulation causes plasma membrane remodelling and anthracycline resistance in breast cancer
(MDPI, 2023)
Breast cancer (BC) is the most common malignancy in women worldwide. While the main systemic treatment option is anthracycline-containing chemotherapy, chemoresistance continues to be an obstacle to ...
Functional genomics approaches to elucidate vulnerabilities of intrinsic and acquired chemotherapy resistance
(MDPI, 2021)
Drug resistance is a commonly unavoidable consequence of cancer treatment that results in therapy failure and disease relapse. Intrinsic (pre-existing) or acquired resistance mechanisms can be drug-specific ...
Atypical cyclin P regulates cancer cell stemness through activation of the WNT pathway
(Springer Nature, 2021)
Purpose: Cancer stem cells represent a cancer cell subpopulation that has been found to be associated with metastasis and chemoresistance. Therefore, it is vital to identify mechanisms regulating cancer ...
Control in patients with advanced cancer: an interpretative phenomenological study
(Springer Nature, 2022)
Background: In the context of life-threatening illness, loss of control is argued as a source of suffering and loss of perceived dignity, whereas having control over the dying process has been seen as ...
To be or not to be a fat burner, that is the question for cpt1c in cancer cells
(Springer Nature, 2023)
There is an urgent need to identify reliable genetic biomarkers for accurate diagnosis, prognosis, and treatment of different tumor types. Described as a prognostic marker for many tumors is the neuronal ...